RFG Advisory’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.05M | Sell |
43,614
-1,832
| -4% | -$47.9K | 0.02% | 554 |
|
|
2026
Q1 | $1.28M | Buy |
45,446
+1,154
| +3% | +$30.7K | 0.02% | 473 |
|
|
2025
Q4 | $1.1M | Sell |
44,292
-5,651
| -11% | -$143K | 0.02% | 500 |
|
|
2025
Q3 | $1.27M | Sell |
49,943
-25,886
| -34% | -$639K | 0.03% | 432 |
|
|
2025
Q2 | $1.84M | Buy |
75,829
+5,420
| +8% | +$126K | 0.04% | 327 |
|
|
2025
Q1 | $1.78M | Buy |
70,409
+20,546
| +41% | +$538K | 0.05% | 298 |
|
|
2024
Q4 | $1.32M | Sell |
49,863
-6,267
| -11% | -$170K | 0.04% | 322 |
|
|
2024
Q3 | $1.62M | Sell |
56,130
-10,333
| -16% | -$301K | 0.05% | 289 |
|
|
2024
Q2 | $1.86M | Sell |
66,463
-35,816
| -35% | -$986K | 0.06% | 230 |
|
|
2024
Q1 | $2.84M | Buy |
102,279
+44,703
| +78% | +$1.24M | 0.1% | 165 |
|
|
2023
Q4 | $1.66M | Sell |
57,576
-7,358
| -11% | -$222K | 0.06% | 234 |
|
|
2023
Q3 | $2.15M | Sell |
64,934
-12,985
| -17% | -$459K | 0.1% | 162 |
|
|
2023
Q2 | $2.86M | Buy |
77,919
+3,344
| +4% | +$130K | 0.13% | 120 |
|
|
2023
Q1 | $3.04M | Sell |
74,575
-4,351
| -6% | -$188K | 0.15% | 119 |
|
|
2022
Q4 | $3.48M | Buy |
78,926
+324
| +0.4% | +$15.5K | 0.18% | 102 |
|
|
2022
Q3 | $3.72M | Buy |
78,602
+5,592
| +8% | +$272K | 0.21% | 95 |
|
|
2022
Q2 | $3.6M | Buy |
73,010
+21,431
| +42% | +$1.09M | 0.21% | 87 |
|
|
2022
Q1 | $2.67M | Sell |
51,579
-1,572
| -3% | -$81.6K | 0.17% | 82 |
|
|
2021
Q4 | $3.14M | Buy |
53,151
+6,807
| +15% | +$337K | 0.22% | 68 |
|
|
2021
Q3 | $1.99M | Buy |
46,344
+726
| +2% | +$32.2K | 0.16% | 98 |
|
|
2021
Q2 | $1.79M | Buy |
45,618
+632
| +1% | +$24.6K | 0.16% | 104 |
|
|
2021
Q1 | $1.63M | Sell |
44,986
-734
| -2% | -$26.1K | 0.18% | 97 |
|
|
2020
Q4 | $1.7M | Sell |
45,720
-3,248
| -7% | -$119K | 0.22% | 86 |
|
|
2020
Q3 | $1.71M | Buy |
48,968
+1,166
| +2% | +$40.9K | 0.24% | 85 |
|
|
2020
Q2 | $1.48M | Buy |
47,802
+1,742
| +4% | +$59.2K | 0.23% | 89 |
|
|
2020
Q1 | $1.43M | Buy |
46,060
+1,511
| +3% | +$51.5K | 0.27% | 79 |
|
|
2019
Q4 | $1.66M | Buy |
44,549
+2,141
| +5% | +$76.3K | 0.28% | 73 |
|
|
2019
Q3 | $1.45M | Buy |
42,408
+5,478
| +15% | +$199K | 0.29% | 69 |
|
|
2019
Q2 | $1.52M | Buy |
36,930
+9,886
| +37% | +$393K | 0.35% | 64 |
|
|
2019
Q1 | $1.09M | Sell |
27,044
-12,892
| -32% | -$516K | 0.28% | 76 |
|
|
2018
Q4 | $1.65M | Buy |
39,936
+1,525
| +4% | +$63.3K | 0.41% | 44 |
|
|
2018
Q3 | $1.61M | Buy |
38,411
+7,366
| +24% | +$284K | 0.42% | 55 |
|
|
2018
Q2 | $1.07M | Buy |
31,045
+4,868
| +19% | +$166K | 0.32% | 55 |
|
|
2018
Q1 | $881K | Sell |
26,177
-76
| -0.3% | -$2.61K | 0.33% | 54 |
|
|
2017
Q4 | $907K | Sell |
26,253
-1,543
| -6% | -$52.6K | 0.42% | 55 |
|
|
2017
Q3 | $951K | Buy |
27,796
+496
| +2% | +$15.9K | 0.59% | 31 |
|
|
2017
Q2 | $866K | Buy |
27,300
+212
| +0.8% | +$6.69K | 0.6% | 30 |
|
|
2017
Q1 | $879K | Buy |
27,088
+9,312
| +52% | +$294K | 0.66% | 35 |
|
|
2016
Q4 | $569K | Hold |
17,776
| – | – | 0.54% | 34 |
|
|
2016
Q3 | $569K | Sell |
17,776
-175
| -1% | -$5.85K | 0.52% | 35 |
|
|
2016
Q2 | $600K | Buy |
17,951
+2,524
| +16% | +$80.6K | 0.52% | 34 |
|
|
2016
Q1 | $434K | Buy |
+15,427
| New | +$441K | 0.34% | 54 |
|
|
2015
Q3 | – | Sell |
-12,797
| Closed | -$407K | – | 128 |
|
|
2015
Q2 | $407K | Buy |
+12,797
| New | +$417K | 0.18% | 88 |
|
Other funds holding PFE
RFG Advisory's PFE Position: Q2 2026 in Review
RFG Advisory reduced its Pfizer (PFE) stake by 4% in Q2 2026, selling an estimated $47.9K and leaving 43,614 shares worth $1.05M. The position accounts for 0.02% of the portfolio, ranked #554.
RFG Advisory first reported a position in PFE in Q2 2015 and has held it in 43 quarters since. The position peaked at $3.72M in Q3 2022. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- RFG Advisory held 43,614 shares of Pfizer worth $1.05M as of Q2 2026.
- RFG Advisory sold 1,832 Pfizer shares in Q2 2026, an estimated $47.9K.
- Pfizer made up 0.02% of RFG Advisory's portfolio in Q2 2026, its #554 holding.
- RFG Advisory first reported a position in Pfizer in Q2 2015 and has held it in 43 quarters since.
- RFG Advisory's Pfizer position peaked at $3.72M in Q3 2022.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on RFG Advisory's 13F filing for Q2 2026, filed 15 Jul 2026.